Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
24 oct. 2024 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...
Precision Neurodegenerative Disease Global Market Report 2024-2028: Key Growth Opportunities in GLP-1 RA and Insulin for AD and PD Patients and Neurotech-based Precision Therapies
26 sept. 2024 06h02 HE
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Precision Neurodegenerative Disease Market, Global, 2024-2028" report has been added to ResearchAndMarkets.com's offering.The rising global...
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
14 août 2024 08h30 HE
|
Vaccinex, Inc.
Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
Molecular Diagnostics for Neurodegenerative Diseases Technology Research Report 2024-2028 Featuring Synaps Dx, AgenT Biotech, Urvogelbio, Resonant, and Neurodex
01 août 2024 04h46 HE
|
Research and Markets
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024-2028" report has been added to ResearchAndMarkets.com's...
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
31 juil. 2024 09h00 HE
|
Vaccinex, Inc.
Positive data for SIGNAL-AD trial of Pepinemab in Alzheimer’s Disease affirm expectation of a novel mechanism to delay progression of Alzheimer’s disease
United States Frontotemporal Dementia Market to Experience Steady Growth Through 2028
28 mars 2024 17h56 HE
|
Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "United States Frontotemporal Dementia Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...
OrphAI Therapeutics receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European Union
15 févr. 2024 10h38 HE
|
OrphAI Therapeutics Inc.
GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today...
Neurodegenerative Disease Market Size To Reach USD 96.4 Billion By 2032 | DataHorizzon Research
12 févr. 2024 07h10 HE
|
DataHorizzon Research
Fort Collins, Colorado, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Neurodegenerative Disease Market size was valued at USD 51.2 Billion in 2023 and is anticipated to reach USD 96.4 Billion by 2032 at a...
Neurodegenerative Disease Market projected to reach USD 69.8 Billion by 2030, growing at a CAGR of 6.2% during the forecast period of 2023-2030 - Claims by MarketDigits in its recent study
28 nov. 2023 08h00 HE
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Nov. 28, 2023 (GLOBE NEWSWIRE) -- According to a research report "Neurodegenerative Disease Market, By Indication Type (Alzheimer's Disease, Huntington Disease, Multiple Sclerosis,...
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
26 sept. 2023 01h15 HE
|
Novartis Pharma AG
Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from...